Tolerability of Rofecoxib versus Naproxen
Authors: Jeffrey R. Lisse, Monica Perlman, Adam B. Polis, Gregory P. Geba
Journal: Annals of Internal Medicine (2004)

Letters15 June 2004Tolerability of Rofecoxib versus NaproxenJeffrey R. Lisse, MD, Monica Perlman, MD, MPH, Adam B. Polis, MA, and Gregory P. Geba, MD, MPHJeffrey R. Lisse, MDFrom University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486.Search for more papers by this author, Monica Perlman, MD, MPHFrom University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486.Search for more papers by this author, Adam B. Polis, MAFrom University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486.Search for more papers by this author, and Gregory P. Geba, MD, MPHFrom University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-12-200406150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:It is important to understand differences between dual cyclooxygenase-inhibiting NSAIDs and coxibs for effective use in appropriate populations. The ADVANTAGE (Assessment of Differences between Vioxx And Naproxen To Ascertain Gastrointestinal tolerability and Effectiveness) study was the largest trial to enroll patients with osteoarthritis using less restrictive entry criteria. In addition, it permitted use of low-dose aspirin during the trial and involved a sample that was characteristic of patients seen in clinical practice with typical comorbid conditions. Treatment of osteoarthritis with rofecoxib and naproxen in this setting was designed to study “real-world” conditions. Other important coxib studies, such as ...References1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-8. [PMID: 11087881] CrossrefMedlineGoogle Scholar2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized, controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-55. [PMID: 10979111] CrossrefMedlineGoogle Scholar3. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al . Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-8. [PMID: 11696466] CrossrefMedlineGoogle Scholar4. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al . Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-17. [PMID: 11752357] CrossrefMedlineGoogle Scholar5. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford). 2000;39 Suppl 2 13-20. [PMID: 11276797] CrossrefMedlineGoogle Scholar6. Fendrick AM. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Cleve Clin J Med. 2002;69 Suppl 1 SI59-64. [PMID: 12086296] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Arizona, Tuscon, AZ 85711; Scripps Clinic and Research Foundation, San Diego, CA 92037; and Merck & Co., Inc., West Point, PA 19486, and Richboro, PA 19486. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis Jeffrey R. Lisse , Monica Perlman , Gunnar Johansson , James R. Shoemaker , Joy Schechtman , Carol S. Skalky , Mary E. Dixon , Adam B. Polis , Arthur J. Mollen , Gregory P. Geba , and Tolerability of Rofecoxib versus Naproxen Lonnie B. Hanauer Tolerability of Rofecoxib versus Naproxen John M. Rusche Tolerability of Rofecoxib versus Naproxen M. L. Jenkinson Metrics 15 June 2004Volume 140, Issue 12Page: 1060KeywordsAdverse reactionsAspirinNSAIDsOsteoarthritisPopulation statisticsRelative riskRheumatoid arthritisSafetySafety studiesUlcers ePublished: 15 June 2004 Issue Published: 15 June 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...